If you’re having hormone therapy for prostate cancer, you may notice changes in your hair and skin. Androgen deprivation therapy (ADT), particularly treatment that lowers testosterone, can make hair on your chest, legs and pubic area thinner and slow your beard growth. Your skin may also feel drier or more sensitive, although significant scalp hair loss is less common with standard ADT. The changes you experience depend partly on which medicines you receive.
If you stop temporary hormone therapy and your testosterone levels recover, some changes may improve, although this can take time. If you notice persistent hair loss, a rash or uncomfortable skin changes, speak to your doctor for advice.
Why Can Lower Testosterone Change Your Hair and Skin?
Testosterone affects more than your sexual function. It influences hair follicles and the sebaceous glands that produce sebum, your skin’s natural oil. When treatment lowers testosterone or blocks androgen activity, your body hair may grow more slowly and your skin may become less oily. If your skin was previously oily, you might notice this difference more clearly, although not everyone experiences the same changes.
Your hair can also respond differently depending on where it grows on your body. For example, your chest or leg hair may become thinner, while your scalp hair may behave differently. These changes vary from person to person, so you may notice only small differences or more noticeable changes during treatment.
Hair and Skin Changes During Prostate Cancer Hormone Therapy
| Change | How strongly is it linked to treatment? | When to ask for advice |
| Reduced body hair | Recognised possible ADT effect | If sudden or unusually extensive |
| Slower beard growth | Can occur with reduced androgen activity | If hair loss becomes sharply patchy |
| Scalp-hair loss | Less common with standard ADT | If sudden, severe or accompanied by scalp inflammation |
| Reduced skin oiliness | Biologically plausible with lower androgen activity | If dryness becomes painful or cracked |
| Dry skin | Can occur but has many possible causes | If persistent, severe or itchy |
| Hot-flush redness | Usually temporary flushing | If redness persists or becomes painful/itchy |
| Drug rash | Particularly relevant to some agents such as apalutamide | Report new or spreading rash promptly |
| Blistering or peeling rash | Rare but potentially serious | Seek emergency medical assessment |
Does Hormone Therapy Make You Lose Body Hair?
Yes, hormone therapy can make your body hair thinner and slower to grow. You may notice less hair on your chest, legs, face or pubic area and find that you need to shave less often.
These changes usually happen gradually and vary from person to person. If you experience sudden or rapid hair loss, speak to your doctor to check for other possible causes.
Research Insight
Androgen receptors are present in several skin structures, and androgen signalling influences terminal hair growth, sebaceous-gland development and sebum production. This provides a biological explanation for why reducing androgen activity can change body-hair growth and skin oiliness.
However, skin can also produce and metabolise androgens locally, and androgen sensitivity varies between tissues and individuals. That is why reduced testosterone does not produce an identical pattern of hair or skin changes in every person.
Can Your Beard and Facial Hair Become Thinner?
Yes, hormone therapy that reduces androgen activity can slow beard growth, and you may notice softer or less dense facial hair. Some men also notice a patchier appearance or find that they need to shave less often as testosterone levels fall. However, the extent of these changes varies between individuals.
Although this change isn’t dangerous, it can affect how you feel about your appearance. If losing your beard’s thickness bothers you, it’s worth discussing with your doctor rather than keeping your concerns to yourself.
What Happens to Pubic and Chest Hair?

During hormone therapy, you may notice that your chest and pubic hair becomes thinner, softer or slower to grow as your testosterone levels fall. Some men experience only a small change, while others notice a more obvious reduction in hair coverage.
These changes usually develop gradually over several months, so you may not notice them straight away. If you’re receiving long-term treatment, you may see the difference become more noticeable over time.
Does Hormone Therapy Cause Scalp Hair Loss?
Hormone therapy can affect your scalp hair, although significant scalp-hair loss is less common than body-hair thinning. You may notice that your hair becomes thinner, drier or more brittle rather than falling out completely. Your experience can also depend on other medicines and cancer treatments.
If you develop sudden, patchy or severe scalp-hair loss, speak to your doctor, especially if you’re also receiving chemotherapy. Your team can assess other possible causes. Hair changes caused by hormone therapy may improve after treatment ends, but regrowth varies and may be incomplete.
UK Guidance Note
Prostate Cancer UK lists loss of body hair as a possible side effect of hormone therapy because testosterone contributes to hair growth. It also notes that scalp-hair loss is less common and that more research is needed to show how common this side effect is.
This is useful reassurance, but sudden or marked scalp-hair loss should still prompt consideration of other causes rather than being assumed to be ADT.
Could Hormone Therapy Actually Slow Male-Pattern Baldness?
Hormone therapy may slow male-pattern baldness in some men because it reduces androgen activity, which can contribute to scalp hair loss. However, your response depends on your genetics and other factors, so you shouldn’t expect your hair to become thicker or bald areas to regrow.
Hormone therapy isn’t a treatment for baldness, and age, nutrition, illness and other medicines can still affect your hair. Your scalp hair may respond differently from your body hair, so changes can be difficult to predict.
How Can You Look After Your Hair During Treatment?
If your scalp or hair feels different during treatment, gentle care can help reduce avoidable irritation and breakage:
- Use a mild shampoo: Choose a product that does not irritate your scalp.
- Avoid very hot water: Lukewarm water may feel more comfortable if the scalp is dry or sensitive.
- Limit excessive heat: Use a cooler hairdryer setting and avoid repeatedly overheating the hair.
- Brush gently: Avoid pulling or aggressive brushing if your hair feels fragile.
- Watch for sudden changes: Rapid, patchy or substantial hair loss should be medically reviewed.
- Check other possible causes: Thyroid problems, nutritional deficiency, illness, chemotherapy or other medicines may also cause hair loss.
Hair-care measures can reduce irritation and breakage, but they cannot prevent androgen-related changes in hair growth.
Can Hormone Therapy Make Your Skin Drier?

Yes, you may notice drier skin during prostate cancer hormone therapy. Lower androgen activity can influence the glands that produce your skin’s natural oils, which may contribute to dryness. You might experience tightness after showering, flaky patches or dryness on your face, arms or legs. However, other medicines, skin conditions and environmental factors may also contribute.
To help your skin feel more comfortable, use lukewarm water, a soap-free cleanser and an unperfumed moisturiser after washing. Avoid strongly fragranced products if your skin feels sensitive or irritated.
Does Skin Become Less Oily on ADT?
Your skin may become less oily during hormone therapy because androgen activity helps regulate sebum production. You might notice less oiliness around your forehead or nose, and some people may experience an improvement in acne. However, this is not guaranteed, and changes in skin oiliness alone do not show how well your cancer treatment is working.
Some treatments can still cause acne, rashes or irritation. Speak to your doctor about persistent or uncomfortable skin changes.
Can Hormone Therapy Cause a Rash?
Yes, some hormone therapy medicines can cause a rash, itching, redness or hives. If you notice new skin changes after starting a tablet or injection, tell your doctor or cancer team and let them know when the symptoms began.
You can photograph your rash to show your treatment team, particularly if it changes before your appointment. Don’t assume every rash is a harmless treatment effect, because some reactions require prompt medical assessment or specific treatment. If you develop breathing difficulties or swelling of your face, lips, tongue or throat, seek emergency help immediately.
Clinical Note
Mild dryness or changes in oiliness can usually be managed with simple skin care. A new drug eruption is different and may present with widespread redness, itchy patches or other new lesions after a medicine is started.
Apalutamide is particularly associated with dermatological adverse events, so patients receiving it should report a new rash early. Early recognition and management may allow safer treatment decisions and reduce progression to more severe reactions.
When Is a Skin Reaction Urgent?
Mild dryness or a small rash is not usually an emergency. Seek urgent assessment if a rash spreads rapidly, becomes painful, blisters or peels, or comes with fever, mouth sores or painful eyes. If you take apalutamide and develop symptoms suggesting a severe skin reaction, stop taking it and seek emergency medical care. Breathing difficulty or swelling of your face, lips, tongue or throat also requires emergency help.
If you receive hormone therapy injections, some tenderness or bruising may occur. However, worsening redness, swelling, discharge or fever needs prompt medical assessment. Don’t assume sudden or severe skin changes are simply a normal treatment side effect.
Evidence Note
A 2022 study by Pan and colleagues assessed 303 patients receiving apalutamide. Dermatological adverse events affected 71 patients (23.4%), with a median onset of 77 days. Among the reported skin events, maculopapular rashes and xerosis (dry skin) were common presentations. These figures describe that study population and do not predict your individual risk.
Rare severe cutaneous reactions have also been reported. A 2026 review identified 18 published cases of severe reactions linked to apalutamide, including DRESS, SJS/TEN and AGEP. Because this evidence comes from reported cases rather than population-level incidence data, it shows that clinicians should recognise these reactions but does not mean they are common.
Can Hot Flushes Change the Way Your Skin Looks?

Yes, during a hot flush, your face and neck may suddenly feel hot and look red or darker, depending on your skin tone. This is a temporary response to increased blood flow near the skin, often accompanied by sweating, rather than permanent skin damage.
Sweating can sometimes irritate your skin, especially in body folds. You can help by keeping the area dry, changing damp clothes and wearing breathable fabrics. If a rash persists, speak to your doctor to check for other possible causes.
Can These Appearance Changes Affect How You Feel About Yourself?
Yes, changes to your hair, skin and body can affect how you feel about your appearance and confidence. If you’ve had the same beard for years or notice less chest hair, you may feel that your body looks unfamiliar. It’s possible to appreciate that treatment is helping control your prostate cancer while still feeling unhappy about these changes.
You don’t have to dismiss these feelings just because the changes seem medically minor. Talk to your partner or doctor if they affect your confidence, relationships or social life. Psychological or psychosexual support may also help you adjust and feel more comfortable with your changing body.
Will Hair Grow Back When Hormone Therapy Stops?
If you stop temporary hormone therapy, body hair and treatment-related scalp-hair changes may improve as testosterone levels recover, but the amount and timing of regrowth vary. Your testosterone may take months or longer to recover after the final injection, particularly after prolonged treatment. Some hair changes may persist even if your hormone levels improve.
Natural ageing also affects hair growth, so regrowth may not restore your hair’s previous thickness or appearance.
Will Your Skin Return to Normal After Treatment Ends?
Many skin changes caused by hormone therapy, such as dryness or reduced oiliness, may improve after treatment ends. As your testosterone levels recover, your skin may gradually feel less dry and return to producing more natural oil.
Recovery varies with your testosterone levels, age and other factors. Ask your doctor if dryness, irritation or other skin changes persist.
When Should You Mention Hair or Skin Changes to Your Cancer Team?

You should tell your cancer team about hair or skin changes whenever they concern you. Gradual thinning of body hair or mild changes in scalp texture can be expected, but sudden patchy hair loss, severe scalp inflammation, a spreading rash or persistent itching should be checked.
Bring a list of your medicines so your team can identify possible causes and discuss suitable treatment. Don’t stop hormone therapy on your own because of appearance changes. Your doctor can advise whether you need skin treatment, a medication review or a referral to a dermatologist.
Myth vs Fact
| Myth | Fact |
| Everyone on ADT loses their hair. | Body-hair thinning can occur, while major scalp-hair loss is less common. |
| Hormone therapy affects scalp and body hair in exactly the same way. | Different hair follicles respond differently to androgen signalling. |
| Dry skin proves your testosterone is very low. | Dryness can have many causes and does not measure testosterone suppression. |
| ADT is a treatment for male-pattern baldness. | Reduced androgen signalling may influence scalp hair, but prostate cancer treatment is not a baldness treatment. |
| Every rash is a normal hormone-therapy side effect. | New rashes may need assessment, particularly with drugs such as apalutamide. |
| Skin peeling or blistering can wait until the next routine appointment. | Rapidly spreading, painful, blistering or peeling reactions need urgent assessment. |
| Hair and skin always return completely to normal when treatment stops. | Some changes may improve, but recovery varies and may be incomplete. |
| You should stop hormone therapy yourself if you develop a rash. | For a mild rash, contact your cancer team promptly. If you take apalutamide and develop a severe blistering or peeling rash, stop taking it and seek emergency care. |
Key Takeaways
- Hormone therapy can reduce body-hair growth because androgen signalling contributes to terminal hair growth.
- Beard, chest, leg and pubic hair may become less dense or slower growing.
- Significant scalp-hair loss is less common with standard ADT.
- Marked or sudden scalp-hair loss may have another cause and should be assessed.
- Androgens influence sebaceous-gland activity, but skin responses to ADT vary.
- Dry skin should not automatically be assumed to be caused by low testosterone.
Frequently Asked Questions
1. Can hormone therapy for prostate cancer cause hair and skin changes?
Yes. Prostate cancer hormone therapy can lower testosterone or block androgen activity, which may affect hair growth and skin oil production. You might notice thinner body hair, slower beard growth or drier skin, although your experience depends on the medicine you receive.
2. Does hormone therapy make you lose body hair?
Yes, your chest, leg and pubic hair may become thinner, softer or slower to grow. These changes usually develop gradually and vary from person to person.
3. Can hormone therapy make your beard thinner?
Yes, lower testosterone can slow beard growth, making facial hair less dense or patchier. You may also find that you need to shave less often.
4. Does hormone therapy cause scalp hair loss?
Significant scalp hair loss is less common with standard androgen deprivation therapy (ADT) than thinning of body hair. However, your scalp hair may become thinner, drier or more brittle, and sudden hair loss should be checked by your doctor.
5. Can hormone therapy slow male-pattern baldness?
Reduced androgen activity may slow male-pattern baldness in some men, but the effect varies. Hormone therapy is not a treatment for baldness and cannot guarantee hair regrowth.
6. Can hormone therapy make your skin dry or less oily?
Yes, lower testosterone can reduce your skin’s natural oil production, leading to dryness, tightness or flaking. Using an unperfumed moisturiser and a gentle cleanser may help keep your skin comfortable.
7. Can prostate cancer hormone therapy cause a skin rash?
Yes. Medicines such as apalutamide can cause rashes, itching or other skin reactions. Tell your cancer team promptly about a new rash. Blistering, peeling, a rash with fever or mouth sores need emergency assessment. Call 999 for breathing difficulties or swelling of your face or throat.
8. Will your hair grow back after hormone therapy stops?
Your body hair and treatment-related scalp hair changes may improve after treatment ends. Regrowth depends on testosterone recovery, your age and treatment duration, and your hair may not return completely to its previous thickness.
9. Will your skin return to normal after hormone therapy?
Dryness and reduced oiliness may improve as your testosterone levels recover. However, the extent of recovery varies, and some changes may persist.
10. When should you discuss hair or skin changes with your cancer team?
Speak to your cancer team about sudden hair loss, persistent itching, severe scalp inflammation or a spreading rash. Blistering, skin peeling, mouth sores or breathing difficulties need emergency care. Your clinicians can review your medicines and advise whether any treatment needs changing.
Final Thoughts: Hair and Skin Changes on Prostate Cancer Hormone Therapy
Hormone therapy for prostate cancer can affect your body hair, beard growth and skin, leaving you with thinner hair or drier, more sensitive skin. Some changes may improve after treatment ends, but recovery depends on your testosterone levels, age and treatment duration. If you notice persistent hair loss, a spreading rash or uncomfortable skin changes, speak to your cancer team for advice. Do not stop treatment for ordinary appearance changes without medical advice. However, if you take apalutamide and develop signs of a severe skin reaction, stop it and seek emergency care.
If you’re concerned about hair loss, dry skin or other changes during prostate cancer hormone therapy, contact Prostate Clinic London for specialist advice about your symptoms, treatment-related side effects and available support, or to arrange a consultation tailored to your needs.
References:
- Prostate Cancer UK (2025) How hormone therapy affects you. Available at: https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/how-hormone-therapy-affects-you/
- Del Rosso, J.Q. et al. (2020) ‘Androgens, androgen receptors, and the skin: from the laboratory to the clinic with emphasis on clinical and therapeutic implications’, Journal of Drugs in Dermatology, 19(3, Suppl. 1), pp. s30–s35. Available at: https://pubmed.ncbi.nlm.nih.gov/32550699/
- Del Rosso, J.Q. and Kircik, L. (2024) ‘The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris’, Journal of Dermatological Treatment, 35(1), article 2298878. Available at: https://pubmed.ncbi.nlm.nih.gov/38192024/
- Pan, A. et al. (2022) ‘Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide’, The Journal of Urology, 207(5), pp. 1010–1019. Available at: https://pubmed.ncbi.nlm.nih.gov/35020444/
- Birtle, A.J. et al. (2024) ‘Early identification and management of patients with rash on apalutamide’, Oncology and Therapy, 12(3), pp. 609–620. Available at: https://pubmed.ncbi.nlm.nih.gov/39088147/
- Wang, T., Liu, S. and Yuan, R. (2026) ‘Apalutamide-induced severe cutaneous adverse reactions in prostate cancer: a comprehensive review of reported cases and clinical strategies’, Frontiers in Pharmacology, 17, article 1769981. Available at: https://pubmed.ncbi.nlm.nih.gov/41993591/